Aerodiol® versus the transdermal route: Perspectives for patient preference

Maturitas

Volumn 38, Issue SUPPL.1, 2001, Pages

  Lopes, Patrice ^a   Rozenberg, Serge ^b   De Graaf, Jan ^c   Fernandez Villoria, E ^d   Marianowski, L ^c  

^a Hopital Mere Enfant CHU de Nantes   (France)

^b SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

^c Fundacion Jimenez Diaz ^*

^d Hospital UniversitarioFundación Jiménez Díaz   (Spain)

Author keywords

Aerodiol; Estradiol; Kupperman index

Indexed keywords

ESTRADIOL;

AEROSOL; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ESTROGEN THERAPY; FEMALE; HOT FLUSH; HUMAN; INTRADERMAL DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; METHODOLOGY; MULTICENTER STUDY; PATIENT COMPLIANCE; PATIENT SATISFACTION; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, INTRANASAL; AEROSOLS; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HOT FLASHES; HUMANS; PATIENT COMPLIANCE; PATIENT SATISFACTION; POSTMENOPAUSE;

EID: 10644230236     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0378-5122(01)00202-x     Document Type: Article

References (30)

1. Steingold K, Laufer L, Chetkowski R, DeFazio J, Matt D, Meldrum D, Judd H. Treatment of hot flashes with transdermal estradiol administration. J Clin Endocrinol Metab 1985;61:627-32.
2. Fantl J, Cardozo L, McClish D and the Hormones and Urogenital Therapy Committee. Estrogen therapy in the management of urinary incontinence in postmenopausal women: a meta-analysis. First report of the hormones and urogenital therapy committee. Obstet Gynecol 1994; 83: 12-18.
3. Christiansen C, Lindsay R. Estrogens, bone loss and preservation. Osteoporos Int 1990;1:7-13.
4. Cauley JA, Seeley DG, Ensrud K, Ettinger B, Black D, Cummings SR. Estrogen replacement therapy and fractures in older women. Ann Intern Med 1995;122:9-16.
5. Grodstein F, Stampfer MJ, Manson JE. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996;335:453-61.
6. Calle EE, Miracle-McMahill HL, Thun MJ, Heath CW. Estrogen replacement therapy and risk of fatal colon cancer in a prospective cohort of postmenopausal women. J Natl Cancer Inst 1995;87:517-23.
7. Baldereschi M, Di Carlo A, Lepore V, et al. Estrogen-replacement therapy and Alzheimer's disease in the Italian longitudinal study on aging. Neurology 1998;50:996-1002.
8. Stumpf PG, Trolice MP. Compliance problems with hormone replacement therapy. Obstet Gynecol Clin North Am 1994;21:219-29.
9. Faulkner DL, Young C, Hutchins D, McCollam JS. Patient noncompliance with hormone replacement therapy: a nationwide estimate using a large prescription claims database. Menopause 1998;5:226-9.
10. Ettinger B, Pressman A. Continuation of postmenopausal hormone replacement therapy in a large health maintenance organization: transdermal matrix patch versus oral estrogen therapy. Am J Manag Care 1999;5:779-85.
11. de Lignieres B, Basdevant A, Thomas G, et al. Biological effects of estradiol-17 beta in post-menopausal women: oral versus percutaneous administration. J Clin Endocrinol Metab 1986;62:536-41.
12. Grodstein F, Colditz GA, Stampfer MJ. Postmenopausal hormone use and cholecystectomy in a large prospective study. Obstet Gynecol 1994;83:5-11.
13. O'Connell MB. Pharmacokinetic and pharmacologic variation between different estrogen products. J Clin Pharmacol 1995;35 (Suppl):18S-24S.
14. Stanczyk FZ, Shoupe D, Nunez V, Macias-Gonzales P, Vijod MA, Lobo RA. A randomized comparison of nonoral estradiol delivery in postmenopausal women. Am J Obstet Gynecol 1988;159:1540-6.
15. Frenkel Y, Kopernik G, Lazer S, et al. Acceptability and skin reactions to transdermal estrogen replacement therapy in relation to climate. Maturitas 1994;20:31-6.
16. Ross D, Rees M, Godfree V, et al. Randomised crossover comparison of skin irritation with two transdermal oestradiol patches. Br Med J 1997;315:288.
17. The Transdermal HRT Investigators Group, Amy JJ, Balmer JA, Baumgarten K, et al. A randomized study to compare the effectiveness, tolerability and acceptability of two different transdermal estradiol replacement therapies. Int J Fertil Menopausal Study 1993;38:5-11.
18. Studd J, Pornel B, Marton I, et al., for the Aerodiol Study Group. Efficacy and acceptability of intranasal 17β-oestradiol for menopausal symptoms: randomised dose-response study, Lancet 1999; 353: 1574-1578.
19. Mattsson LA, Christiansen C, Colau J-C, et al. Clinical equivalence of intranasal and oral 17β-estradiol for postmenopausal symptoms. Am J Obstet Gynecol 2000;182: 545-552.
20. Compel A, Bergeron C, Jondet M, et al. Endometrial safety and tolerability of Aerodiol® intranasal estradiol for 1 year, in press.
21. Pelissier C, de Kervasdoue A, Chuong VT, et al. Clinical evaluation, dose-finding and acceptability of Aerodiol®, the pulsed esbrogen therapy for treatment of climacteric symptoms, 2001;37:181-189.
22. Devissaguet JP, Brion N, Lhote O, Deloffre P. Pulsed estrogen therapy: pharmacokinetics of intranasal 17β-estradiol (S 21400) in post menopausal women and comparison with oral and transdermal formulations, Eur J Drug Metab Pharmacokinet 1999; 24: 265-271.
23. Scott RT, Ross B, Anderson C, Archer DF. Pharmacokinetics of percutaneous estradiol: a crossover study using a gel and a transdermal system in comparison woth oral micronized estradiol. Obstet Gynecol 1991;77:758-64.
24. Cano A. Compliance to hormone replacement therapy in menopausal women in a third level academic centre. Maturitas 1994;20:91-9.
25. Rees MC. The need to improve compliance to HRT. Br J Obstet Gynaecol 1997;104(Suppl 16):1-3.
26. Ettinger B, Pressman A, Bradley C. Comparison of continuation of postmenopausal hormone replacement therapy: transdermal versus oral estrogen. Menopause 1998;5:152-6.
27. Bjorn I, Backsrom T. Drug related negative side-effects is a common reason for poor compliance in hormone replacement therapy. Maturitas 1999;32:77-86.
28. Vestergaard P, Hermann AP, Gram J, et al. Improving compliance with hormonal replacement therapy in primary osteoporosis prevention. Maturitas 1997;15:137-45.
29. Stevenson JC. Handling hormone replacement therapy: key issues for the prescriber. Eur J Obstet Gynecol Reprod Biol (Suppl) 1996;64:S25-7.
30. Dayan-Lintzer M, Klein P. Galenique, concertation et observance dans le traitement hormonal de substitution. Contracept Fertil Sex 1999;27:318-21.